Naproxen (NPX) is a non-steroidal anti-inflammatory used for the treatment of rheumatoid arthritis and osteoarthritis, isolated or as pharmacotherapeutic associations. However, NPX oral administration evokes significant adverse effects (such as toxicity to the gastrointestinal tract). In order to reduce systemic side effects, the intraarticular (IA) route has been proposed as an alternative. Although the use of the needle is not removed from the therapeutic scheme, the administration of new pharmaceutical formulations via IA would reduce the uptake of the drug from the site of injection in direction to the systemic circulation, maintaining the drug in the synovial fluid in effective concentrations. In this context, the development of new formulations for controlled release of NPX it would be interesting for reducing the number of injections also increasing the patient compliance. Thus, we propose the incorporation of nanoparticles composed of chitosan-tripolyphosphate (CHI-TPP) in poloxamer (PL) - based hydrogels with different values of hydrophilic-lipophilic balance, aiming the formation of a dual release with thermoreversible properties, but different profiles for sol-gel transition, micellar structure, rheological properties and drug release kinetics. This work aims the development (preparation and characterization), the evaluation of in vitro release and the cytotoxicity of new formulations for controlled release of NPX incorporated into CHI-TPP nanoparticles dispersed in thermoreversible hydrogels, for administration by IA route, looking foward the treatment of arthritis.
News published in Agência FAPESP Newsletter about the scholarship: